PT  - JOURNAL ARTICLE
AU  - Cabecinhas, Ana Rita Goncalves
AU  - Roloff, Tim
AU  - Stange, Madlen
AU  - Bertelli, Claire
AU  - Huber, Michael
AU  - Ramette, Alban
AU  - Chen, Chaoran
AU  - Nadeau, Sarah
AU  - Gerth, Yannick
AU  - Yerly, Sabine
AU  - Opota, Onya
AU  - Pillonel, Trestan
AU  - Schuster, Tobias
AU  - Metzger, Cesar M.J.A.
AU  - Sieber, Jonas
AU  - Bel, Michael
AU  - Wohlwend, Nadia
AU  - Baumann, Christian
AU  - Koch, Michel C.
AU  - Bittel, Pascal
AU  - Leuzinger, Karoline
AU  - Brunner, Myrta
AU  - Suter-Riniker, Franziska
AU  - Berlinger, Livia
AU  - Søgaard, Kirstine K.
AU  - Beckmann, Christiane
AU  - Noppen, Christoph
AU  - Redondo, Maurice
AU  - Steffen, Ingrid
AU  - Seth-Smith, Helena M.B.
AU  - Mari, Alfredo
AU  - Lienhard, Reto
AU  - Risch, Martin
AU  - Nolte, Oliver
AU  - Eckerle, Isabella
AU  - Lucchini, Gladys Martinetti
AU  - Hodcroft, Emma B.
AU  - Neher, Richard A.
AU  - Stadler, Tanja
AU  - Hirsch, Hans H.
AU  - Leib, Stephen L.
AU  - Risch, Lorenz
AU  - Kaiser, Laurent
AU  - Trkola, Alexandra
AU  - Greub, Gilbert
AU  - Egli, Adrian
TI  - SARS-CoV-2 N501Y introductions and transmissions in Switzerland from beginning of October 2020 to February 2021 – implementation of Swiss-wide diagnostic screening and whole genome sequencing
AID  - 10.1101/2021.02.11.21251589
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.11.21251589
4099  - http://medrxiv.org/content/early/2021/02/12/2021.02.11.21251589.short
4100  - http://medrxiv.org/content/early/2021/02/12/2021.02.11.21251589.full
AB  - The rapid spread of the SARS-CoV-2 lineages B.1.1.7 (N501Y.V1) throughout the UK, B.1.351 (N501Y.V2) in South Africa, and P.1 (B.1.1.28.1; N501Y.V3) in Brazil has led to the definition of variants of concern (VoCs) and recommendations by the European Center for Disease Prevention and Control (ECDC) and World Health Organization (WHO) for lineage specific surveillance. In Switzerland, during the last weeks of December 2020, we established a nationwide screening protocol across multiple laboratories, focusing first on epidemiological definitions based on travel history and the S gene dropout in certain diagnostic systems. In January 2021, we validated and implemented an N501Y-specific PCR to rapidly screen for VoCs, which are then confirmed using amplicon sequencing or whole genome sequencing (WGS). A total of 3492 VoCs have been identified since the detection of the first Swiss case in October 2020, with 1370 being B1.1.7, 61 B.1.351, and none P.1. The remaining 2061 cases of VoCs have been described without further lineage specification. In this paper, we describe the nationwide coordination and implementation process across laboratories, public health institutions, and researchers, the first results of our N501Y-specific variant screening, and the phylogenetic analysis of all available WGS data in Switzerland, that together identified the early introduction events and subsequent community spreading of the VoCs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted in close collaboration with the FOPH and is part of an epidemiological assessment (Communicable Diseases Legislation - Epidemics Act). In addition, the study was approved as a multi-center study by the leading ethical committee (Ethik Kommission Nordwest- und Zentralschweiz, EKNZ; Approval number 2019-01291).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenomic data is semi-publicly available on GISAID.org. Summary statistics were made available directly by the Federal Office of Public Health (FOPH) Switzerland.